Karthik Suresh

Associate Professor

Johns Hopkins University

United States

Research Interests

Explore related searches

Professors in United States

Contact this professor

Get a free first email built on one of their papers, ready for you to edit and send yourself.

About

Dr. Karthik Suresh is an Associate Professor at Johns Hopkins University, USA. His research focuses on bioenergetics, metabolism in pulmonary vascular diseases, and the effects of metabolic dysregulation on health outcomes. Recent publications include studies on the tricarboxylic acid cycle in right ventricular maladaptation, mitochondrial quality control in pulmonary arterial hypertension, and the impact of sleep fragmentation on pneumonia recovery.

Articles (16)

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2023

Year:

2023

Year:

2023

Year:

2023

Year:

2023

Year:

2023

Year:

2023

Collaborators (12)

Todd Kolb

Johns Hopkins University

UNITED STATES

View details

Hongyang Pi

University of Washington

UNITED STATES

View details

ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

Karthik Suresh

Research Interests

Explore related searches

Contact this professor

About

Articles (16)

Distinct single-cell transcriptional profile in CD4+ T-lymphocytes among obese children with asthma

Dysregulated Tricarboxylic Acid Cycle Metabolism Is Associated With Right Ventricular Maladaptation in Pulmonary Vascular Disease

Bioenergetics and metabolism of the pulmonary endothelium. Scientific session I: ReSPIRE 2025

Development of a preclinical model of ICU-associated sleep fragmentation and effects on pneumonia recovery in mice

Targeting Endothelial Cell Mitochondrial Quality Control in PAH

A novel interaction between aquaporin 1 and caspase-3 in pulmonary arterial smooth muscle cells

Aberrant long-chain fatty acid metabolism associated with evolving systemic sclerosis-associated pulmonary arterial hypertension

Pulmonary toxicity of immune checkpoint immunotherapy

Proteomic Signatures of Right Ventricular Outcomes in Pulmonary Arterial Hypertension

MK2 nonenzymatically promotes nuclear translocation of caspase-3 and resultant apoptosis.

Tumor MK2 transcript levels are associated with improved response to chemotherapy and patient survival in non-small cell lung cancer.

Spatial and temporal resolution of metabolic dysregulation in the Sugen hypoxia model of pulmonary hypertension

“Lyn”king Emphysema and Cancer Development: Insights from Src Family Kinase Gain-of-Function Models

Metabolic profiling of in vivo right ventricular function and exercise performance in pulmonary arterial hypertension

Society for Immunotherapy of Cancer (SITC) consensus definitions for immune checkpoint inhibitor-associated immune-related adverse events (irAEs) terminology.

Post hoc survival analyses using RNAseq data: handle with care

Collaborators (12)

Todd Kolb

Ryan J. Tedford

Tijana Tuhy

Ali Shojaie

Mario Naranjo Tovar

Larissa Shimoda

Robert Hagan

sebastien bonnet

Mahendra Damarla

Ian Adcock

Samuel Rayner

Hongyang Pi

Make your next move.